Travere Therapeutics (TVTX) Profit After Tax (2011 - 2026)
Travere Therapeutics (TVTX) posted Profit After Tax of -$36.6 million for Q1 2026, down 1441.22% on a QoQ basis from $2.7 million in Q4 2025, and up 11.22% year-over-year from -$32.9 million in Q1 2025.
Travere Therapeutics (TVTX) Profit After Tax (2011 - 2026) Analysis & Trends
Travere Therapeutics' Profit After Tax history runs 16 years deep, the most recent figure standing at -$36.6 million for Q1 2026.
- Quarterly Profit After Tax rose 11.22% year-over-year to -$36.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.9 million (up 90.71% YoY) and the FY2025 annual result came in at -$25.5 million, up 92.02% from the prior year.
- Profit After Tax was -$36.6 million for Q1 2026 at Travere Therapeutics, down from $2.7 million in the prior quarter.
- Across five years, Profit After Tax topped out at $25.7 million in Q3 2025 and bottomed at -$136.1 million in Q1 2024.
- A 5-year average of -$62.7 million and a median of -$70.4 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax slumped 135.87% — and 2025, when it jumped 147.43%.
- Travere Therapeutics' Profit After Tax stood at -$85.6 million in 2022, then dropped by 3.46% to -$88.6 million in 2023, then surged by 33.04% to -$59.3 million in 2024, then jumped by 104.6% to $2.7 million in 2025, then slumped by 1441.22% to -$36.6 million in 2026.
- Business Quant data shows TVTX's Profit After Tax at -$36.6 million in Q1 2026, $2.7 million in Q4 2025, and $25.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | -36.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.60 Mn |
| Dec 31, 2025 | 2.73 Mn |
| Sep 30, 2025 | 25.71 Mn |
| Jun 30, 2025 | -12.76 Mn |
| Mar 31, 2025 | -41.23 Mn |
| Dec 31, 2024 | -59.33 Mn |
| Sep 30, 2024 | -54.19 Mn |
| Jun 30, 2024 | -70.41 Mn |
| Mar 31, 2024 | -136.06 Mn |
| Dec 31, 2023 | -88.60 Mn |
| Sep 30, 2023 | -89.24 Mn |
| Jun 30, 2023 | -101.93 Mn |
| Mar 31, 2023 | -86.33 Mn |
| Dec 31, 2022 | -85.64 Mn |
| Sep 30, 2022 | -84.06 Mn |
| Jun 30, 2022 | -67.03 Mn |
| Mar 31, 2022 | -81.75 Mn |
| Dec 31, 2021 | -51.23 Mn |
| Sep 30, 2021 | -35.64 Mn |
| Jun 30, 2021 | -39.39 Mn |